XMFWildWeasel

Stephen D. Simpson

XMFWildWeasel’s Activity

Yesterday

NL

Article

XMFWildWeasel published an article 6:30 PM

St. Jude Medical Inc.: In-Line Is Just Not Good Enough

Expectations may be the bigger challenge for St. Jude these days

NL

Article

XMFWildWeasel published an article 6:30 PM

Abbott Labs Earnings: Still Marking Time

Abbot's long-term potential is masked by its weak near-term growth.

Tue Apr 15

NL

Article

XMFWildWeasel published an article 6:30 PM

How Much Has Merck Shaken Up the Hepatitis C Race?

Recent data presentations at the EASL conference highlight the emerging competition in hepatitis C.

NL

Article

XMFWildWeasel published an article 4:26 PM

Johnson & Johnson's Earnings Report Impresses

Persistent strength in pharmaceuticals drives a strong beat, but valuation seems appropriate.

NL

Article

XMFWildWeasel published an article 2:30 PM

This Forgotten Pharma Could Be a Hit for Your Portfolio

Roche combines a very deep oncology pipeline with some of the best growth and margins in Pharma

Mon Apr 14

NL

Article

XMFWildWeasel published an article 6:30 PM

Edwards Lifesciences Corp Scores A Potentially Major Legal Ruling Against Medtronic

Edwards Lifesciences wins a rare injunction that could block competition to its Sapien valve through 2016.

Thu Apr 10

NL

Article

XMFWildWeasel published an article 12:42 PM

What's Behind Intuitive Surgical Inc's Revenue Miss?

Intuitive misses already-lowered Q1 expectations by a wide amount.

Wed Apr 9

NL

Article

XMFWildWeasel published an article 2:30 PM

Can Perrigo Company PLC Continue Its Bull Run?

Perrigo has leveraged a dominant position in store-brand OTC healthcare into good margins, returns, and cash flow.

Mon Apr 7

NL

Article

XMFWildWeasel published an article 6:30 PM

Mallinckrodt plc Takes a Big Swing for Growth

In buying Questcor, Mallinckrodt is acquiring exceptional potential for earnings, controversy, and disappointment

NL

Article

XMFWildWeasel published an article 2:30 PM

Pfizer Inc's Palbociclib Delivers the Goods

Palbociclib looks poised to be a multibillion-dollar drug for Pfizer.

NL

Article

XMFWildWeasel published an article 9:30 AM

Is There Opportunity in the Eye-Care Sector?

Eye care companies like Essilor, Luxottica, and Cooper Companies offer good exposure to emerging-market growth and less regulatory and reimbursement risk.

NL

Article

XMFWildWeasel published an article 9:00 AM

Can Express Scripts Holding Co. Beat Expectations Again?

Despite a long run of success and market-leading share, the Street seems skeptical that Express Scripts can find more savings

Fri Apr 4

NL

Article

XMFWildWeasel published an article 6:30 PM

Can DaVita HealthCare Partners Inc's Run Last?

DaVita's focus on outcomes-based medicine could be the right recipe for the future

Thu Apr 3

NL

Article

XMFWildWeasel published an article 2:03 PM

Monsanto Company's Balanced Growth Proves Stronger Than the Headwinds

Monsanto outperformed in a quarter where analysts feared a miss, and the company is loaded with long-term incremental growth drivers.

Wed Apr 2

NL

Article

XMFWildWeasel published an article 11:45 AM

Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?

Fresenius has significant market share in dialysis, but reimbursement pressures in the U.S. are a significant challenge.

Tue Apr 1

NL

Article

XMFWildWeasel published an article 2:30 PM

Can This Drive Growth for Amarin Corporation plc?

A co-promotion agreement with Kowa seems like a reasonable way to drive badly-needed sales growth

Mon Mar 31

NL

Article

XMFWildWeasel published an article 2:14 PM

What You Need to Know About the Agilent Technologies Split

Agilent's spin-off should unlock more value from the life science and diagnostics operations.

Thu Mar 27

NL

Article

XMFWildWeasel published an article 6:30 PM

Is Teva Pharmaceutical Industries Ltd Turning a Corner?

Teva has rebounded sharply as management addresses multiple Street concerns

NL

Article

XMFWildWeasel published an article 1:34 PM

Exelixis Inc's Comet Fails To Dazzle

The lack of an early halt to the COMET-1 study raises serious questions about whether Exelixis can stand out in a more competitive field in prostate cancer

NL

Article

XMFWildWeasel published an article 11:46 AM

Will Baxter International Inc's Split Unlock Shareholder Value?

Baxter's announced intention to split should improve the perceived value of the company's device and drug operations.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75540
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to XMFWildWeasel’s CAPS page

Boards Stats & Trivia

Old School Fool
Board Posts 12
Recs Received 19
People who have rec'd these posts 13
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board Motley Fool Inside Value
Very First Post A IV Stocks That Interest You post. (6/15/2005)
Percentage of Posts Rec'd 66.67 %
Show XMFWildWeasel’s 10 Latest Posts